These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 16109464

  • 1. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
    Konski A, Sherman E, Krahn M, Bremner K, Beck JR, Watkins-Bruner D, Pilepich M.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):788-94. PubMed ID: 16109464
    [Abstract] [Full Text] [Related]

  • 2. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G.
    Cancer; 2006 Jan 01; 106(1):51-7. PubMed ID: 16323171
    [Abstract] [Full Text] [Related]

  • 3. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
    Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):408-15. PubMed ID: 16887291
    [Abstract] [Full Text] [Related]

  • 4. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
    Konski A.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1373-8. PubMed ID: 15590167
    [Abstract] [Full Text] [Related]

  • 5. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P, Kwias Z, Martenka DJ.
    Neoplasma; 2007 Dec 01; 54(1):7-15. PubMed ID: 17203887
    [Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M.
    J Urol; 2005 Aug 01; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [Abstract] [Full Text] [Related]

  • 7. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.
    Cancer; 1996 May 01; 77(9):1854-61. PubMed ID: 8646685
    [Abstract] [Full Text] [Related]

  • 8. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM, Radiation Therapy Oncology Group Trial 9902.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):672-8. PubMed ID: 18990504
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L, Peters J, Roome C, Stein K.
    BJU Int; 2012 Apr 01; 109(8):1183-92. PubMed ID: 21883830
    [Abstract] [Full Text] [Related]

  • 10. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D.
    Urology; 2005 Oct 01; 66(4):835-9. PubMed ID: 16230148
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 01; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 12. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.
    Aprikian AG, Fleshner N, Langleben A, Hames J.
    Can J Urol; 2003 Oct 01; 10(5):1986-94. PubMed ID: 14633326
    [Abstract] [Full Text] [Related]

  • 13. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer].
    Nishimura S, Arai Y, Usami M, Kanetake H, Naito S, Akaza H.
    Gan To Kagaku Ryoho; 2007 Apr 01; 34(4):589-95. PubMed ID: 17431346
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S.
    J Clin Oncol; 2005 Sep 20; 23(27):6561-8. PubMed ID: 16170164
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE, El-Ouagari K, Karnon J, Sofrygin O.
    Breast Cancer Res Treat; 2008 Apr 20; 108(3):375-87. PubMed ID: 17653859
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, Hirano D, Takimoto Y, Kamoto T, Ogawa O, Sumiyoshi Y, Shimazaki J, Kakizoe T, Japanese Study Group for Locally Advanced Prostate Cancer.
    Jpn J Clin Oncol; 2006 Dec 20; 36(12):789-93. PubMed ID: 17082219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.